PON2

Across TCGA pan-cancer cohorts, PON2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PON2 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PON2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PON2 expression acts as an unfavorable survival marker.

HNSC, LUAD, and CCRCC are the cancer types where PON2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.903	0.981	.007	34	view →
LUAD	DFS	Tertile	All	0.397	0.930	.004	30	view →
CCRCC	OS	Median	III,IV	0.561	0.813	.017	22	view →
LSCC	OS	Median	II,III,IV	0.599	0.892	.008	12	view →
PDAC	DFS	Tertile	III,IV	0.374	0.895	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PON2–HNSC (DFS)

Open the HNSC breakdown →